Please provide your email address to receive an email when new articles are posted on . One journal reviewer told Donald P. McDonnell, PhD, the research should be “banned from the literature.” A ...
SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results. Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results